Botswana Beat Cohort Study and the Safety of Dolutegravir in Pregnancy
MAR 23, 2019 | CONTAGION® EDITORIAL STAFF
Segment Description: Ava Avalos, MD, director of the Careena Centre for Health in Botswana, details the effects of a dolutegravir-based regimen on pregnancy.
Interview transcript (modified slightly for readability):
Contagion®: Safety of ART in pregnancy is a big focus in HIV care. Your study reported no neural tube defects in the 77 deliveries included. Can you expand a little more on that?
Dr. Avalos: "Well we look at all clinical outcomes, including tuberculosis, pregnancy, and opportunistic infections, and so we had 77 women in that cohort of over 2000 patients that were pregnant in the first year and 11 of those had [dolutegravir] exposure preconception and all of them had good outcomes from pregnancy; there were no neural tube defects. And it really does seem like the neural tube defect in general in Botswana is fading, but we'll know when the study ends in April."
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512